apyx medical - APYX

APYX

Close Chg Chg %
3.63 0.05 1.38%

Closed Market

3.68

+0.05 (1.38%)

Volume: 44.04K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Company Overview: apyx medical - APYX

APYX Key Data

Open

$3.60

Day Range

3.50 - 3.69

52 Week Range

0.83 - 4.50

Market Cap

$153.93M

Shares Outstanding

41.83M

Public Float

36.10M

Beta

1.54

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.27

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

146.98K

 

APYX Performance

1 Week
 
1.10%
 
1 Month
 
17.95%
 
3 Months
 
5.14%
 
1 Year
 
271.72%
 
5 Years
 
-62.30%
 

APYX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About apyx medical - APYX

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used by the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Surgical Aesthetics and Original Equipment Manufacturer (OEM). The Surgical Aesthetics segment consists of the Helium Plasma Technology lines, which include Renuvion and J-Plasma. The OEM segment focuses on designing, development, and manufacturing electrosurgical equipment and medical devices by producing generators, medical devices and related accessories. The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

APYX At a Glance

Apyx Medical Corp.
5115 Ulmerton Road
Clearwater, Florida 33760-4004
Phone 1-727-384-2323 Revenue 52.84M
Industry Medical Specialties Net Income -11,211,000.00
Sector Health Technology 2025 Sales Growth 9.858%
Fiscal Year-end 12 / 2026 Employees 205
View SEC Filings

APYX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.722
Price to Book Ratio 10.059
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -26.20
Enterprise Value to Sales 2.871
Total Debt to Enterprise Value 0.259

APYX Efficiency

Revenue/Employee 257,775.61
Income Per Employee -54,687.805
Receivables Turnover 3.15
Total Asset Turnover 0.803

APYX Liquidity

Current Ratio 4.998
Quick Ratio 4.262
Cash Ratio 2.713

APYX Profitability

Gross Margin 36.017
Operating Margin -12.198
Pretax Margin -20.504
Net Margin -21.215
Return on Assets -17.027
Return on Equity -77.99
Return on Total Capital -20.807
Return on Invested Capital -21.139

APYX Capital Structure

Total Debt to Total Equity 270.564
Total Debt to Total Capital 73.014
Total Debt to Total Assets 58.857
Long-Term Debt to Equity 267.62
Long-Term Debt to Total Capital 72.22
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Apyx Medical - APYX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
44.51M 52.35M 48.10M 52.84M
Sales Growth
-8.26% +17.61% -8.11% +9.86%
Cost of Goods Sold (COGS) incl D&A
34.00M 38.23M 36.09M 33.81M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
890.00K 692.00K 599.00K 655.00K
Depreciation
700.00K 692.00K 599.00K 655.00K
Amortization of Intangibles
- - - 190.00K
-
COGS Growth
+4.82% +12.43% -5.58% -6.33%
Gross Income
10.51M 14.12M 12.01M 19.03M
Gross Income Growth
-34.64% +34.37% -14.98% +58.52%
Gross Profit Margin
+23.61% +26.98% +24.96% +36.02%
2022 2023 2024 2025 5-year trend
SG&A Expense
34.07M 34.07M 30.85M 25.48M
Research & Development
4.54M 4.84M 5.08M 3.37M
Other SG&A
29.53M 29.23M 25.77M 22.11M
SGA Growth
+11.61% +0.00% -9.45% -17.42%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 3.09M
-
EBIT after Unusual Expense
(23.56M) (23.04M) (18.84M) (6.45M)
Non Operating Income/Expense
666.00K 4.24M 1.45M 1.20M
Non-Operating Interest Income
157.00K 921.00K 1.61M 1.11M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
15.00K 2.48M 5.91M 5.59M
Interest Expense Growth
+50.00% +16,420.00% +138.38% -5.38%
Gross Interest Expense
15.00K 2.48M 5.91M 5.59M
Interest Capitalized
- - - -
-
Pretax Income
(22.91M) (21.28M) (23.31M) (10.84M)
Pretax Income Growth
-54.60% +7.11% -9.52% +53.51%
Pretax Margin
-51.47% -40.65% -48.45% -20.50%
Income Tax
367.00K (2.43M) 252.00K 270.00K
Income Tax - Current - Domestic
5.34M 1.76M 4.28M 23.00K
Income Tax - Current - Foreign
124.00K 185.00K 228.00K 247.00K
Income Tax - Deferred - Domestic
- (5.10M) (4.38M) (4.25M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(23.28M) (18.85M) (23.56M) (11.11M)
Minority Interest Expense
(94.00K) (137.00K) (96.00K) 106.00K
Net Income
(23.18M) (18.71M) (23.46M) (11.21M)
Net Income Growth
-52.81% +19.28% -25.38% +52.22%
Net Margin Growth
-52.09% -35.75% -48.78% -21.22%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(23.18M) (18.71M) (23.46M) (11.21M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(23.18M) (18.71M) (23.46M) (11.21M)
EPS (Basic)
-0.6717 -0.5405 -0.6602 -0.2728
EPS (Basic) Growth
-52.00% +19.53% -22.15% +58.68%
Basic Shares Outstanding
34.52M 34.62M 35.54M 41.09M
EPS (Diluted)
-0.6717 -0.5405 -0.6602 -0.2728
EPS (Diluted) Growth
-52.00% +19.53% -22.15% +58.68%
Diluted Shares Outstanding
34.52M 34.62M 35.54M 41.09M
EBITDA
(22.67M) (19.26M) (18.25M) (5.79M)
EBITDA Growth
-67.38% +15.05% +5.26% +68.26%
EBITDA Margin
-50.94% -36.79% -37.93% -10.96%

Snapshot

Average Recommendation BUY Average Target Price 6.00
Number of Ratings 5 Current Quarters Estimate -0.09
FY Report Date 06 / 2026 Current Year's Estimate -0.322
Last Quarter’s Earnings -0.11 Median PE on CY Estimate N/A
Year Ago Earnings -0.27 Next Fiscal Year Estimate -0.282
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.09 -0.08 -0.32 -0.28
High Estimates -0.07 -0.06 -0.30 -0.20
Low Estimate -0.10 -0.10 -0.36 -0.35
Coefficient of Variance -13.61 -18.09 -8.33 -20.28

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 4
OVERWEIGHT 0 0 0
HOLD 0 0 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Apyx Medical - APYX

Date Name Shares Transaction Value
May 20, 2025 Moshe Citronowicz Sr. V.P. of Operations 36,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Matthew C. Hill Chief Financial Officer 100,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Lawrence J. Waldman Director 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Stavros G. Vizirgianakis Director 128,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Minnie V. Baylor-Henry Director 59,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Charles D. Goodwin Chief Executive Officer; Director 193,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Wendy Levine Director 64,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Apyx Medical in the News